{"id":76794,"date":"2026-08-27T14:36:10","date_gmt":"2026-08-27T06:36:10","guid":{"rendered":"https:\/\/flcube.com\/?p=76794"},"modified":"2026-08-27T14:36:10","modified_gmt":"2026-08-27T06:36:10","slug":"insilico-medicine-swings-to-profitability-as-revenue-surges-287-in-1h-2026-rentosertib-advances-to-phase-3","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76794","title":{"rendered":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3696:HKG\">HKG: 3696<\/a>) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately <strong>USD 106.3 million<\/strong>, a <strong>287.2% year\u2011on\u2011year increase<\/strong>, and a net profit of approximately <strong>USD 35.54 million<\/strong> versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive <strong>turnaround to profitability<\/strong>. With cash and investment portfolio of <strong>USD 584.8 million<\/strong> at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset <strong>Rentosertib<\/strong> entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).<\/p>\n\n\n\n<h2 id=\"h-financial-highlights-1h-2026\" class=\"wp-block-heading\">Financial Highlights \u2013 1H 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>1H 2026<\/th><th>1H 2025<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Total Revenue<\/td><td>~USD 106.3 million<\/td><td>~USD 27.5 million*<\/td><td>+287.2%<\/td><\/tr><tr><td>Net Profit<\/td><td>~USD 35.54 million<\/td><td>Net loss of USD 19.22 million<\/td><td>Swung to profit<\/td><\/tr><tr><td>Drug Discovery &amp; Pipeline Development Revenue<\/td><td>USD 103.1 million<\/td><td>~USD 25.7 million*<\/td><td>+300%+<\/td><\/tr><tr><td>Software Solutions Revenue<\/td><td>USD 2.697 million<\/td><td>\u2014<\/td><td>Steady growth<\/td><\/tr><tr><td>Cash &amp; Investment Portfolio (end\u2011Jun)<\/td><td>USD 584.8 million<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><tr><td>2026 Announced Transaction Value (to date)<\/td><td>~USD 7.3 billion<\/td><td>\u2014<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><em>*Prior\u2011period figures implied by reported growth rates.<\/em><\/p>\n\n\n\n<h2 id=\"h-revenue-drivers-amp-business-development\" class=\"wp-block-heading\">Revenue Drivers &amp; Business Development<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BD Deal Engine:<\/strong> Drug discovery and pipeline development revenue surged to <strong>USD 103.1 million<\/strong>, up over <strong>300% year on year<\/strong>, driven primarily by substantial upfront payments from a series of key business development (BD) deals reached during the period, alongside continued milestone payments from existing collaborations<\/li>\n\n\n\n<li><strong>Deal Flow:<\/strong> As of the latest practicable date, the total value of transactions announced by <strong>Insilico Medicine<\/strong> in 2026 amounted to approximately <strong>USD 7.3 billion<\/strong><\/li>\n\n\n\n<li><strong>Second Growth Engine:<\/strong> Software solutions revenue grew steadily to <strong>USD 2.697 million<\/strong>, indicating that the <strong>MMAI Gym<\/strong> model training and evaluation ecosystem \u2014 under construction since 2026 \u2014 is gradually emerging as the company&#8217;s second growth pillar<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-ai-driven-r-amp-d-productivity-amp-pipeline-progress\" class=\"wp-block-heading\">AI\u2011Driven R&amp;D Productivity &amp; Pipeline Progress<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Preclinical Candidates:<\/strong> Since the beginning of 2026, Insilico has announced the nomination of <strong>nine preclinical candidates (PCCs)<\/strong>, including <strong>ISM0676<\/strong> (oral small\u2011molecule GIPR antagonist) and <strong>ISM5059<\/strong> (peripherally restricted NLRP3 inhibitor), among others<\/li>\n\n\n\n<li><strong>Clinical Momentum:<\/strong> <strong>Eight clinical advancements<\/strong> achieved across the pipeline in the same period<\/li>\n\n\n\n<li><strong>Lead Asset \u2013 Rentosertib:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Initiated a <strong>large\u2011scale Phase 3 clinical trial in China<\/strong> for <strong>idiopathic pulmonary fibrosis (IPF)<\/strong><\/li>\n\n\n\n<li>An <strong>inhaled formulation of Rentosertib<\/strong> has also received clinical trial approval in China<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Generative AI Advantage:<\/strong> The company continues to leverage generative AI to improve R&amp;D efficiency, shorten development cycles, and reduce R&amp;D costs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Profitability Inflection:<\/strong> The swing from a USD 19.22 million loss to a USD 35.54 million profit marks a landmark validation of Insilico&#8217;s AI\u2011driven business model \u2014 rare among biotechs at this stage and potentially re\u2011rating for the stock.<\/li>\n\n\n\n<li><strong>Deal\u2011Funded Growth:<\/strong> With ~USD 7.3 billion in announced 2026 transaction value, the company&#8217;s BD pipeline provides durable visibility on upfronts and milestones, de\u2011risking near\u2011term financial performance beyond 1H.<\/li>\n\n\n\n<li><strong>Rentosertib as Flagship Catalyst:<\/strong> The large\u2011scale Phase 3 launch in IPF \u2014 a disease with severe unmet need and limited approved therapies \u2014 positions Rentosertib as the pivotal value driver, with the inhaled formulation adding differentiated delivery optionality.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Phase 3 enrollment and interim readouts for Rentosertib, conversion of announced deals into executed agreements and milestone payments, progression of the nine newly nominated PCCs, and scaling of the MMAI Gym software ecosystem.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment advice. Interim results are unaudited; statements regarding pipeline development, BD transactions, and future financial performance are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements and filings from Insilico Medicine for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600543_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082600543_c.\"><\/object><a id=\"wp-block-file--media-34a52c81-750c-4467-bd62-dc0a8ca97eb1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600543_c.pdf\">2026082600543_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082600543_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-34a52c81-750c-4467-bd62-dc0a8ca97eb1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June&#8230;<\/p>\n","protected":false},"author":1,"featured_media":76797,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[99,27,4514,164],"class_list":["post-76794","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-ai","tag-finanical-reports","tag-hkg-3696","tag-insilico-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year\u2011on\u2011year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76794\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year\u2011on\u2011year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76794\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T06:36:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3\",\"datePublished\":\"2026-08-27T06:36:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794\"},\"wordCount\":600,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2703.webp\",\"keywords\":[\"AI\",\"Finanical Reports\",\"HKG: 3696\",\"Insilico Medicine\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76794#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76794\",\"name\":\"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2703.webp\",\"datePublished\":\"2026-08-27T06:36:10+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year\u2011on\u2011year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76794\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76794#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3 - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year\u2011on\u2011year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76794","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3","og_description":"Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year\u2011on\u2011year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).","og_url":"https:\/\/flcube.com\/?p=76794","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T06:36:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76794#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76794"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3","datePublished":"2026-08-27T06:36:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76794"},"wordCount":600,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=76794#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp","keywords":["AI","Finanical Reports","HKG: 3696","Insilico Medicine"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76794#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76794","url":"https:\/\/flcube.com\/?p=76794","name":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=76794#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=76794#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp","datePublished":"2026-08-27T06:36:10+00:00","description":"Insilico Medicine (HKG: 3696) released its interim results report for the six months ended June 30, 2026, reporting total revenue of approximately USD 106.3 million, a 287.2% year\u2011on\u2011year increase, and a net profit of approximately USD 35.54 million versus a net loss of USD 19.22 million in the same period last year \u2014 marking a decisive turnaround to profitability. With cash and investment portfolio of USD 584.8 million at period end, the AI drug discovery pioneer is converting a record wave of business development deals and pipeline milestones into sustained financial performance, anchored by its lead asset Rentosertib entering a large\u2011scale Phase 3 trial in idiopathic pulmonary fibrosis (IPF).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76794#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76794"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=76794#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp","width":1080,"height":608,"caption":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76794#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2703.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76794"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76794\/revisions"}],"predecessor-version":[{"id":76798,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76794\/revisions\/76798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/76797"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}